Climb Bio (CLYM) Liabilities and Shareholders Equity (2020 - 2026)

Climb Bio's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $152.4 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 24.09% year-over-year to $152.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $694.8 million (down 19.78% YoY) and the FY2025 annual result came in at $167.7 million, down 22.77% from the prior year.
• Liabilities and Shareholders Equity was $152.4 million for Q1 2026 at Climb Bio, down from $167.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $226.0 million in Q2 2024 and bottomed at $109.3 million in Q1 2024.
• A 5-year average of $160.0 million and a median of $152.4 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity retreated 24.83% — and 2024, when it jumped 97.1%.
• Climb Bio's Liabilities and Shareholders Equity stood at $135.0 million in 2022, then fell by 18.17% to $110.5 million in 2023, then soared by 96.6% to $217.2 million in 2024, then fell by 22.77% to $167.7 million in 2025, then dropped by 9.16% to $152.4 million in 2026.
• Business Quant data shows CLYM's Liabilities and Shareholders Equity at $152.4 million in Q1 2026, $167.7 million in Q4 2025, and $182.3 million in Q3 2025.